Navigation Links
Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
Date:4/15/2008

FRESNO, Calif., April 15 /PRNewswire/ -- Chairman & CEO, Paul Willis stated, "Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company's chief operating officer and president of operations." Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans -- and people around the world -- to consume a special type of selenium known as SelenoExcell(R). SelenoExcell(R) was found in a gold-standard human clinical trial to dramatically reduce colon, prostate, and lung cancers.

*(PHOTO 72dpi: Send2Press.com/mediaboom/08-0415-Whitacre_72dpi.jpg)

*(Photo Caption: Dr. Mark E. Whitacre.)

Mark Whitacre is the subject of a motion picture to be filmed starting next month, titled, "The Informant," with box office mega star Matt Damon playing Whitacre. However, Whitacre's real mission in life and main passion for the future is focused on the role of selenium and SelenoExcell(R) as a cancer prevention agent. Cypress believes that with the anticipated media coverage related to the movie, there will be a window of opportunity to raise public awareness for SelenoExcell(R) and cancer prevention.

Awarded his Ph.D. at Cornell University, Dr. Whitacre did his research thesis on the biochemical role of selenium at the cellular level. His research was conducted jointly with a world-renowned selenium scientist, Dr. G.F. Combs, Jr. Dr. Whitacre today stated, "Although sadly underutilized, selenium has the potential to have the most profound impact upon dietary cancer prevention of any nutrient we know of today."

Cancer rates per 100,000 people are about the same as they were 40 years ago! According to the American Cancer Society, 565,650 people are expected to die this year due to cancer in the USA, and 1,437,180 people are expected to have cancer in 2008. "These cancer incidence and death rate
'/>"/>

SOURCE Cypress Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
2. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
3. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
4. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
5. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
6. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
7. Biotage Launches New 24 Well Pyrosequencing(R) System
8. Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract
9. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
10. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
11. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNew...y guidance document for the publication of company...line today by the British Medical Journal (BMJ). "...on of the importance of providing support and guid...cation of study results in the peer-reviewed medic...
(Date:11/30/2009)..., CHICAGO, Nov. 30 Dr. Jessica ...ge Washington University Medical Center in Washing... Breast-Specific Gamma Imaging (BSGI) in clinical ...agnosis of breast cancer today at the annual meeti...SNA). ,, "The purpose of the exhibit was to dem...
(Date:11/30/2009)... , ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCa...day it has completed enrollment in the Phase II cl...2008/2009 recommended strains) VLP vaccine candida...er adults). This randomized, double-blind, active...ility and immunogenicity of two different doses (1...
(Date:11/30/2009)... PDS, a leader in providing sma...nity, announces Pajama Pathology®, evolutioniz... same ‘gold standard’ software used by...orld, but on a ‘cost per slide’ basis....RWEB) November 30, 2009 -- PDS has announced anoth...
Breaking Biology Technology:ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3
... Increased 5-Year Survival Data for Responding Pat...rporated (OTC Bulletin Board: GNTA) announced that...d and Drug Administration (FDA) for its,New Drug A...um) Injection,plus chemotherapy for patients with ...a (CLL). The submission is based on new informatio...
...June 6 DURECT Corporation,(Nasdaq: DRRX ) announ...at,three upcoming life sciences conferences in New...gy and Medical Technology Conference on Thursd...,s Pain Roundtable Conference, on Monday, June 23r... Healthcare Conference on Thursday, June 26th at ...
...une 6 InterMune, Inc.,(Nasdaq: ITMN ) today anno...,Chief Financial Officer of InterMune, will presen...Healthcare Conference in Dana Point, Calif. on,Jun...Hodgman will also,present at the Seventh Annual Ne...hnology Conference in New York on June 12, 2008 at...
Other Biology Technology:Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 3Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 4InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences 2
(Date:11/26/2009)... survey carried out in eight European countries ha...fectious disease pandemic could have a significant...s writing in the open access journal BMC Infectio...on school days and weekends/holidays, finding that... Hens, from Hasselt and Antwerp University, Belgiu...
(Date:11/26/2009)...RSA (methicillin-resistant Staphylococcus Aureus ...ihilation as low-temperature plasma prototype devi... and unfailing bactericidal cocktails. , Two pro...ent disinfection of healthy skin (e.g. hands and f... can pose a lethal threat; and another to shoot ba...
(Date:11/25/2009)...thens, Ga. Bacteria don,t have easy lives. In add... bugs, they have natural enemies called bacterioph... every two days. , Still, bacteria and another ...overed in extreme environments such as deep-sea vo... because they have a built-in defense system that ...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 1Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 2Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 3Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 1Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 2Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 3EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 1EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 2EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 3
... 23, 2007, President Bush stated that, in order to... increase the supply of alternative fuels, by sett...on gallons of renewable and alternative fuels in 2...l refiner subsidy promised in the 2008 Farm Bill a... growers are putting energy needs ahead of environ...
...th breast cancer today are candidates for lumpecto...ast tissue. Results of a UC Davis study, however, ... the same breast are treated with a second lumpect...tment recommendations and cutting the number of ye...rised to find that so many women in our study alm...
...r undertaken of the upper U.S. Gulf Coast suggests...rs could flood large swaths of wetlands this centu...In terms of sea-level increases and river sediment... a time when bays will face conditions they last s...ears ago," said lead researcher John Anderson, the...
Other Biology News:Mandate for biofuels production requires science-based policy and global perspective 2Second lumpectomy for breast cancer reduces survival rates 2Bays on US Gulf Coast vulnerable to flooding 2
Rat Anti-p19ARF Monoclonal Antibody, Unconjugated, Clone 5-C3-1 from Upstate
EDTA, tetrasodium salt from GE Healthcare, formerly Amersham Biosciences
Tracker Datamatrix RS-1* from Micronic BV
GeneAmplimer HIV-1 Control Reagents from Applied Biosystems
Biology Products: